News
VANI
1.700
-5.82%
-0.105
Weekly Report: what happened at VANI last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at VANI last week (0401-0405)?
Weekly Report · 04/08 11:33
Weekly Report: what happened at VANI last week (0325-0329)?
Weekly Report · 04/01 11:30
Vivani Medical: A Growth-Focused Gamble with No Dividend Payouts in Sight
TipRanks · 03/28 06:01
Vivani Medical’s Innovative Obesity Treatment Promises High Compliance and Market Growth: A Strong Buy Recommendation
TipRanks · 03/27 17:16
VANI Stock Earnings: Vivani Medical Beats EPS for Q4 2023
Vivani Medical reported earnings per share of -12 cents. The company did not report any revenue for the quarter. Vivani Medical was above the analyst estimate for EPS of -14 cents in the second quarter. The stock was down 2.7% after the market closed.
Investorplace · 03/26 17:52
Vivani Medical Inc reports results for the quarter ended in December - Earnings Summary
Vivani Medical Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 12 cents per share. Vivani Medical shares had risen by 88.2% this quarter. The lone analyst forecast was for a loss of 14 cents; analysts expected zero.
Reuters · 03/26 14:34
Vivani Medical Updates Investors with Informative Presentations
TipRanks · 03/26 12:42
Vivani Medical GAAP EPS of -$0.12
Seeking Alpha · 03/26 12:38
*Vivani Medical 4Q Loss/Shr 12c >VANI
Dow Jones · 03/26 12:33
Vivani Medical Q4 EPS $(0.12) Beats $(0.14) Estimate
Benzinga · 03/26 12:32
Press Release: Vivani Medical Provides Business -2-
Vivani Medical develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time. The company's lead programs are for the treatment of chronic weight management in obese or overweight patients and type 2 diabetes. Vivani's wholly owned subsidiary Cortigent is developing precision neurostimulation systems.
Dow Jones · 03/26 12:30
Weekly Report: what happened at VANI last week (0318-0322)?
Weekly Report · 03/25 11:33
From Benzinga's Healthcare Summit: Vivani Medical Co-Founder & CEO, Adam Mendelsohn Says Co Is Not In Clinicals Yet, But Hopes To Be There Soon
Benzinga · 03/20 17:25
From Benzinga's Healthcare Summit: Vivani Medical Co-Founder & CEO, Adam Mendelsohn Says 'If Stop You Taking Weight loss Drugs Your Weight Will Come Back Fairly Quickly Co is Working On A Drug Where This Does Not Happen'
Benzinga · 03/20 17:14
Weekly Report: what happened at VANI last week (0311-0315)?
Weekly Report · 03/18 11:31
Weekly Report: what happened at VANI last week (0304-0308)?
Weekly Report · 03/11 11:28
Maxim Group Sticks to Its Buy Rating for Vivani Medical (VANI)
Maxim Group analyst Naz Rahman maintains a Buy rating on Vivani Medical. The company has a one-year high of $7.80 and a low of $0.75. The stock has an analyst consensus of Moderate Buy. Vivani medical is a maker of implantable visual prosthetics.
TipRanks · 03/07 12:38
BUZZ-U.S. STOCKS ON THE MOVE-Silver miners, Albemarle, Pfizer
Federal Reserve Chair Jerome Powell says central bank expects to reduce benchmark interest rate later this year. The Dow Jones Industrial Average was up 0.28% at 38,694.64. Top three S&P 500 percentage gainers: Albemarle, DexCom, Pfizer.
Reuters · 03/06 19:09
BUZZ-U.S. STOCKS ON THE MOVE-Couchbase, Foot Locker, Nordstrom
Federal Reserve Chair Jerome Powell says central bank expects to reduce benchmark interest rate later this year. The Dow Jones Industrial Average was up 0.38% at 38,731.02. The top three S&P 500 percentage gainers were Hewlett Packard, Box and Nordstrom. Nordstrom, Couchbase and Ross Stores were among the biggest losers.
Reuters · 03/06 16:30
More
Webull provides a variety of real-time VANI stock news. You can receive the latest news about Vivani Medical through multiple platforms. This information may help you make smarter investment decisions.
About VANI
Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It is engaged in the development of the Company’s lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively. Its other pipeline product candidates include NPM-139, and OKV-119. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. It operates through two segments: Biopharm Division and Neuromodulation Division. The Company’s implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules.